Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.4.3.13 (
lysyl oxidase
)
1,248
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Neoplastic transformation mediated by ras oncogenes is associated with deregulated expression of genes encoding, for example, various proteases,
lysyl oxidase
, and smooth-muscle alpha-actin. To define the role of these genes in the initiation or maintenance of the ras-transformed state, we compared their steady-state mRNA levels in two different sets of preneoplastic fibroblast lines, ras-transformed clones, and phenotypic revertants derived from them. Compared with the preneoplastic fibroblasts, the ras-transformed derivatives exhibited elevated levels of cathepsin L (major excreted protein), transin (stromelysin I, matrix metalloproteinase-3), and collagenase I (matrix metalloproteinase-1) mRNA but undetectable levels of
lysyl oxidase
mRNA. Partial restoration of
lysyl oxidase
transcription was observed in four of five phenotypic revertants derived from rat FE-8 and NIHpEJcl3 cells. The elevated levels of transin mRNA found in NIHpEJcl3 cells were diminished to the pretransformation level in
interferon
revertants but were not reduced in phenotypic rat FE-8 revertants expressing a high level of the ras oncoprotein. High steady-state levels of collagenase I mRNA were dependent on ras expression but were not closely associated with the transformed phenotype. High levels of cathepsin L mRNA were associated with neither high ras expression nor neoplastic transformation. The downregulation of smooth-muscle alpha-actin, characteristic of transformed cell lines, was not reversible in phenotypic revertants.
...
PMID:Partial restoration of pre-transformation levels of lysyl oxidase and transin mRNAs in phenotypic ras revertants. 772 41
The promoter activity of
lysyl oxidase
(
LOX
), the enzyme involved in collagen and elastin cross-linking and in tumor suppression, was compared in extracellular matrix producing cells and in tumorigenic c-Ha-ras-NIH-3T3 fibroblasts (RS485). The full 2 kb murine
LOX
promoter was very active in 3T6-5 myofibroblast-like cells (MFLC) and vascular smooth muscle cells (SMC) and was inhibited in ras-transformed fibroblasts. Positive cis-acting elements were located around sites of transcription initiation in MFLC and SMC, but neither in RS485 fibroblasts nor in their non-transformed counterparts. The main positive cis-acting segment, at positions -808 to -585, was active in all cells, with the strongest activity in MFLC and SMC, and one segment, at positions -758 to -726, allowed the formation of one master DNA-protein complex with nuclear factors from all cells. The main inhibiting region, at positions -1,362 to -1,176, was active in all fibroblasts, but not in SMC, in an upstream position or in an enhancer/silencer position. This region carries two segments, called LOcoll and LOcol2 for their similarity to COL1A1 and COL1A2 promoter sequences, that were involved in the formation of a large multifactorial DNA complex with nuclear factors from all cells, though slightly for SMC. Another region, carrying a putative
interferon
response element (IRF) at positions -898 to -886, acted negatively on each type of cells. In conclusion, the
LOX
promoter is controlled by cross-talk between positive and negative cis-acting regions that are differentially active in various cells. The -758 to -726 region, with its putative C/EBP site, and the transcription initiation region are likely to play a master role in activating the
LOX
promoter in fibrocompetent MFLC and SMC. While the LOcol1/2 segment, with putative B-Myb binding sites, and the IRF carrying region, work negatively on the
LOX
promoter in transformed cells.
...
PMID:Comparative functional study of the lysyl oxidase promoter in fibroblasts, Ras-transformed fibroblasts, myofibroblasts and smooth muscle cells. 1064 73
Lysyl oxidase is an essential catalyst for the cross-linking of extracellular collagen and elastin. Abnormalities in
lysyl oxidase
activity may contribute to the pathogenesis of arterial diseases characterized by abnormal matrix remodeling. This study tested the hypothesis that
interferon
(
IFN
)-gamma, a proinflammatory cytokine present in aortic aneurysm and arteriosclerotic plaque rupture, downregulates
lysyl oxidase
gene expression in rat aortic smooth muscle cells. Steady-state
lysyl oxidase
mRNA levels decreased in a concentration- and time-dependent manner to 30% of control levels after 24 hours of treatment with IFN-gamma. Cell layer
lysyl oxidase
activity decreased in parallel with the observed changes in steady-state mRNA. Nuclear runoff studies suggested that transcriptional regulation was responsible for at least 40% of the observed downregulation. mRNA decay studies suggested that IFN-gamma also decreased
lysyl oxidase
mRNA half-life from 9 to 6 hours. Downregulation of
lysyl oxidase
by IFN-gamma did not appear to require new protein synthesis. This study documents that IFN-gamma downregulates
lysyl oxidase
gene expression in rat aortic smooth muscle cells by transcriptional and posttranscriptional mechanisms. If similar regulation occurs in vivo, it is possible that IFN-gamma-mediated changes in
lysyl oxidase
may contribute to arterial diseases characterized by abnormal extracellular matrix.
...
PMID:Regulation of lysyl oxidase by interferon-gamma in rat aortic smooth muscle cells. 1076 62